Full-Time

Quality Control Analyst

Deadline 9/15/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

No salary listed

Lyon, France

In Person

Associate's

Category
Biology & Biotech (1)

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • A minimum of 3 years of experience in a pharmaceutical analytical laboratory is required.
  • Confirmed experience with high-performance liquid chromatography is required.
  • Advanced proficiency with Caducée/Empower software is indispensable.
  • Experience in analytical validation, including QI, QO, and QP, is required.
  • Knowledge of data-integrity requirements is required.
  • A BTS/DUT in Chemistry, biological and biochemical analyses, or an equivalent qualification is required.
  • The analyst must be rigorous, work effectively as part of a team, and communicate effectively.
  • The analyst must be trained and qualified for assigned analytical tests requiring qualification.
  • Tasks must be performed in accordance with current good manufacturing practice, environmental health and safety requirements, applicable instructions, procedures, and associated records.
Responsibilities
  • Perform physicochemical analyses on raw materials, intermediate products, and finished products using high-performance liquid chromatography, coulometry, titration, and other methods.
  • Write analytical reports and document results according to applicable procedures.
  • Perform preventive and corrective maintenance on analytical equipment.
  • Analyze data and record verified, reliable results.
  • Initiate quality investigations and conduct laboratory investigations.
  • Manage the sending and receipt of results from subcontractors.
  • Execute analytical tests within agreed timelines.
  • Serve as the primary technical key user for Caducée/Empower in the laboratory.
  • Administer and configure Caducée/Empower, including creating and managing chromatographic methods and configuring acquisition sequences.
  • Train and support new Caducée users through initial training and daily support.
  • Act as the interface between laboratory users and information-technology support to resolve incidents and anomalies.
  • Write and maintain procedures and operating instructions related to Caducée use at the industrial site.
  • Serve as the primary contact during internal audits and regulatory inspections concerning the chromatographic data-management system.
  • Record all raw data, calculations, and required task-related information to comply with good manufacturing practice and data-integrity requirements.
  • Review quality-control data from tests performed by other analysts within the required timelines.
  • Inform the manager promptly of quality or environmental health and safety events, including deviations and out-of-operational-control events.
  • Participate actively in investigations when involved to ensure that investigations and impact assessments are appropriately conducted.
  • Execute assigned corrective and preventive actions related to remediation plans and continuous improvements.
  • Maintain the laboratory, facilities, and laboratory instruments in a condition that supports appropriate quality and safe use.
  • Perform environmental and utilities sampling.
  • Develop remediation plans related to inspection-readiness deviations, observations, and other deviations.
Desired Qualifications
  • Experience as a Caducée/Empower key user or super-user is strongly valued.
  • Strong interpersonal skills and communication ability are valued.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 sales rose 13.6%, while launches grew 49.6% and Dupixent 30.8%.
  • July 2026 FDA approval expanded Sarclisa across all U.S. myeloma indications.
  • Paulo Fontoura assumed R&D leadership on September 1, 2026, accelerating pipeline execution.

What critics are saying

  • Tolebrutinib’s FDA rejection on December 24, 2025 exposed severe liver-injury risk.
  • Dupixent lawsuits consolidated in New Jersey by June 2026 threaten label and damages exposure.
  • Sanofi’s insulin plant needed €400 million German aid on September 8, 2026, signaling supply fragility.

What makes Sanofi unique

  • Dupixent posted €4.17 billion Q1 2026 sales, dominating immunology globally.
  • Sanofi’s July 2026 Sarclisa Escena became the first cancer on-body injector treatment.
  • Sanofi secured Cenrifki EU approval in June 2026, advancing a differentiated MS franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

La Croix
Sep 8th, 2026
EU approves $448M German subsidy to Sanofi for insulin production security

The European Commission has approved a €400 million subsidy from Germany to pharmaceutical company Sanofi to maintain its Frankfurt insulin production site. The Commission stated that without this aid, Sanofi would close the German facility, reducing insulin supply security across the European Economic Area. The subsidy aims to compensate Sanofi for costs related to a service of general economic interest, strengthening insulin supply resilience for German patients. In return, Sanofi must build a new insulin factory in Frankfurt by 31 December 2032 and guarantee minimum annual production of 1.1 tonnes until 2042. Sanofi is among the world's leading insulin producers. The company announced in 2024 a €1.3 billion investment in Frankfurt to construct a new complex replacing existing facilities.

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.